Publications by authors named "Andrea Franchi"
Article Synopsis
- This study evaluated how well Crohn's Disease patients in Italy continued their biologic treatments and the associated healthcare costs.
- A total of 1,398 out of 16,374 identified patients were treated with biologics; higher persistence was observed in those treated with ustekinumab compared to other drugs over a year.
- Overall, while there were differences in treatment persistence, the direct healthcare costs across the different biologic treatments were similar, primarily influenced by the price of the medications used.
Psoriasis is a complex and chronic disease, and, in most cases, therapies are required during all patients' lifetime. The efficacy and safety profiles of biological therapies are well established, but their effectiveness is still open to discussion. We performed a systematic review to summarize how the effectiveness of biological therapies for psoriasis is measured in real-world studies and to understand whether drug survival, a recent alternative outcome to clinical ones, is a recurrent and valid outcome of effectiveness.
View Article and Find Full Text PDFBackground: Incidence and prevalence of Crohn's disease (CD) have increased during the last decades in several world areas. Italian data on CD are scattered between various administrative, educational and scientific sources, and findings are poorly summarized.
Aims: We conducted a review focusing not only on prevalence and incidence of CD in Italy, but also on mortality, treatments, delayed diagnosis and hospitalization.